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Abstract: Etoposide (ETO) is a cytotoxic drug that exerts its effect by increasing reactive oxygen species
(ROS) production. Although ETO is widely used, fast metabolism, poor solubility, systemic toxicity,
and multi-drug resistance induction all limit its administration dosage and its therapeutic efficiency.
In order to address these issues, a biodegradable dendrimer was prepared for entrapping and
protecting ETO and for enhancing its solubility and effectiveness. The achieved dendrimer
complex with ETO (CPX 5) showed the typical properties of a well-functioning delivery system,
i.e., nanospherical morphology (70 nm), optimal Z-potential (−45 mV), good drug loading (37%),
very satisfying entrapment efficiency (53%), and a remarkably improved solubility in biocompatible
solvents. In regards to its cytotoxic activity, CPX 5 was tested on neuroblastoma (NB) cells with very
promising results. In fact, the dendrimer scaffold and ETO are able to exert per se a cytotoxic and
pro-oxidant activity on human NB cells. When CPX 5 is combined with ETO, it shows a synergistic
action, slowly releasing the drug over time and significantly improving and protracting bioactivity.
On the basis of these findings, the prepared ETO reservoir represents a novel biodegradable and
promising device for the delivery of ETO into NB cells.
Keywords: etoposide; lab-made biodegradable dendrimer; nanoparticle formulation; improved
solubility; neuroblastoma cells; synergistic action; protracted release
1. Introduction
In order to exert their anticancer action, the currently used chemotherapeutic drugs are
administered at high doses that, with long-lasting treatment, induce serious secondary toxic effects
in patients. In this context, several strategies have been devised in order to reduce drug toxicity,
such as modifying the schemes and the routes of drug administration. Another strategy, currently
being studied and which is giving promising results, is the administration of chemotherapeutic
drugs entrapped into nanoparticles, which, by sequestering the drug within them and avoiding
direct contact with body fluids, reduce drug toxicity and fast metabolism. Among nanoparticles,
dendrimers [1] are easily transported in the blood [2,3], show a low polydispersion index [4], allow a
greater bioavailability, and improve the pharmacokinetic of the transported drugs thanks to a series of
nonpareil properties [4–6], including a low viscosity [2,3].
Among the drugs, etoposide (ETO) is widely used to treat severe malignancy, but secondary
toxic effects, poor solubility, and the induction of resistance limit its therapeutic efficiency. ETO is
derived from Podophyllotoxin (Figure 1), which is the main chemical component of podophyllin,
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the resin extracted from herbaceous plants known as Podophyllum hexandrum and Podophyllum
peltatum [7,8].
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during the G2/M phase, is the target of ETO [9]. In fact, ETO is cell cycle-specific and accumulates 
only in G2/M1 phase cells [10]. Interestingly, ETO is clinically used, in combination with other 
antineoplastic drugs, for the treatment of patients with neuroblastoma (NB) or many other solid 
tumors [11–13]. Unfortunately, its clinical efficiency is hindered by poor water solubility, metabolic 
and non-metabolic inactivation, drug resistance, myelosuppression, and poor bioavailability [14–16]. 
In addition, high drug concentrations lead to the saturation of the enzyme, with prolonged 
exposure and great cytotoxicity [17–20]. ETO encompasses a trans-fused 7-lactone ring that, by 
enzyme action, is promptly metabolized into trans-hydroxyl acid (1). Moreover, it could epimerize 
into the cis-picro lactone isomer picroetoposide (PETO) (2) that, in turn, is hydrolyzed to cis-hydroxyl 
acid (3) (Figure 2), metabolites losing in vitro biological activity [14,21,22]. 
 
Figure 2. Deactivation of ETO by epimerization. 
Furthermore, ETO is also easily inactivated by non-enzymatic epimerization provoked by weak 
bases. An assumption, concerning the mechanism of the conversion of the trans lactone ring to the 
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In particular, ETO acts by inhibiting topoisomerase II through interactions with the amino acid
residues Asp737, Tyr804, Lys738, and Glu784. Alpha and beta toposisomerase II isoforms are differently
expressed during the cell cycle. In particular, the alpha isoform, whose level increases during the G2/M
phase, is the target of ETO [9]. In fact, ETO is cell cycle-specific and accumulates only in G2/M1 phase
cells [10]. Interestingly, ETO is clinically used, in combination with other antineoplastic drugs, for the
treatment of patients with neuroblastoma (NB) or many other solid tumors [11–13]. Unfortunately,
its clinical efficiency is hindered by poor water solubility, metabolic and non-metabolic inactivation,
drug resistance, myelosuppression, and poor bioavailability [14–16].
In addition, high drug concentrations lead to the saturation of the enzyme, with prolonged
exposure and great cytotoxicity [17–20]. ETO encompasses a trans-fused 7-lactone ring that, by enzyme
action, is promptly metabolized into trans-hydroxyl acid (1). Moreover, it could epimerize into the
cis-picro lactone isomer picroetoposide (PETO) (2) that, in turn, is hydrolyzed to cis-hydroxyl acid (3)
(Figure 2), metabolites losing in vitro biological activity [14,21,22].
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Furthermore, ETO is also easily inactiv ed by non-enzy at c epimerization provoked by weak
bases. An assumption, concerning the mechanism of the conversion of the trans lactone ring to
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the thermodynamically stable cis-lactone, deals with the formation of an enolate at C-2 by proton
abstraction, followed by an inversion of the configuration at C-2 [21,23] (Figure 3).
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Concerning the inactivating process shown in Figure 3, it is reported that PETO can be selectively
produced at pH = 9, while the hydroxyl acid is detectable at pH = 12. At low pH values, the cis-hydroxyl
acid is reverted to PETO [24].
Some years ago, a series of arylamino derivatives of ETO was prepared in order to
achieve compounds more resistant to inactivation and therefore endowed with greater therapeutic
efficiency [25].
The study resulted successful, and 4d-(4”-arylamino)-4’-demethylpodophyllotoxin 7-cyclic acetal,
7-cyclic ether, and 7-lactol were obtained. These compounds proved to have the ability to block
epimerization and the biological deactivation processes, showing activities equal or superior to ETO.
Despite the promising results, the synthetic path, composed of several steps and the laborious
and long purification operations through chromatographic columns, necessary after each step can
compromise the actual feasibility of this apparently appealing strategy.
In the last decades, great advances have been made in drug delivery engineered techniques,
and, nowadays, the most attractive, fast, and low cost prospect for protecting and delivering ETO,
overcoming its limitations, and improving its therapeutic efficiency and clinical applications is
represented by the use of proper carrier nano-devices.
Nanoparticles are extensively inspected to prepare multifunctional smart materials [26–30] and
are widely employed in various biomedical applications [31–49].
In this regard, inorganic nanohybrid constructs, consisting of layered double hydroxides (LDHs)
intercalated with VP16 (ETO phosphate), have been successfully synthesized and characterized [50].
The prepared nanoparticles showed an average diameter of 62.5 nm, Z-potential of +20.5 mV,
drug loading (DL%) of 21.94%, and a profile of sustained release of the drug. In vitro tests showed that
VP16-LDH nanoparticles exerted a high cytotoxic effect on cancer cells while being less toxic for healthy
cells [50]. However, although the results obtained from the employment of LDHs are promising,
further improvements could be important in order to enhance some physicochemical properties,
which are pivotal for a well-functioning nanosized drug delivery system, such as Z-potential [51–53]
and an increase in DL%. Among the strategies adopted, the use of dendrimer offers interesting
perspectives [1–6]. The commercially available poly (amidoamine) dendrimers (PAMAMs) are well
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performant in vitro, but they are not advisable for clinical applications because, if not properly modified,
are harmful to cell membranes [54]. On the contrary, polyester dendrimer scaffolds show very attractive
results because they are highly biodegradable and respectful to physiological membranes [4,55,56].
Starting from this background, the aim of this work was to develop a successful strategy
to ameliorate ETO stability and solubility, thus improving its delivering and anticancer activity.
Complying with the most modern trends that suggest using nanotechnology, dendrimer nanoparticles
were selected as a device to obtain an ETO drug delivery system (DDS) with a more promising
Z-potential and an improved DL% in comparison to that previously achieved. In this regard, a fifth
generation polyester-based dendrimer (4) that was successful in enhancing stability, reducing fast
metabolism, and improving several beneficial activity of a natural polyphenol was prepared as
previously described [57–62].
By using dendrimer 4 for entrapping ETO in its inner cavities, a protective shell around ETO
was created. The ETO-loaded nanoparticles that were achieved (namely CPX 5) showed an improved
solubility in solvents where it was already soluble, such as dimethyl sulfoxide (DMSO) (by 1.3 times),
but also a highly improved solubility in hydrophilic and biocompatible solvents such as ethanol
and water (by 37–390 times). The major water solubility of ETO-loaded nanoparticles might assure,
in vivo, a better solubility in gastrointestinal fluids, which represents a crucial property for necessary
bioavailability. On the other hand, the preservation of a certain hydrophobic nature will allow a
good compatibility with physiologic membranes and, consequently, a higher level of absorbability
in the gastrointestinal tract (GIT). CPX showed a spherical morphology, a particle size of about
70 nm, and an optimal Z-potential (−45 mV), matching the values that typically assure low toxicity,
high residence time in blood, low polydispersion, and stability in solution [50–52]. The drug loading of
37% was determined by UV determinations. The biological activity of CPX 5, made of the dendrimer
scaffold and ETO, was tested on HTLA-230, a high risk MYCN-amplified human neuroblastoma cell
line. The unexpected but exciting results revealed that the dendrimer scaffold has a cytotoxic and
pro-oxidant effect comparable to that of ETO. Furthermore, it acts in synergy with the complexed ETO,
thus increasing its cytotoxic and pro-oxidant action in a time-dependent manner. These events are
potentially due to a slow and protracted release of ETO that, entrapped in the dendrimer, is unable to
act immediately, leading to a reduced systemic toxicity. The herein prepared ETO reservoir represents
a novel biodegradable nanoformulation of ETO with a scaffold-assisted, improved, and sustained
cytotoxicity on NB cells.
2. Materials and Methods
2.1. Chemicals and Instruments
All reagents and solvents were purchased from Merck (formerly Sigma-Aldrich, Darmstadt,
Germany). Dendron intermediates were synthetized to achieve dendrimer 4, i.e., D4BnA, D4BnOH,
D5BnA, and D5ACOOH were prepared as previously reported [57–59] and their chemical structures
are available in Figure S1. Fifth generation polyester-based biodegradable dendrimer 4 was
prepared according to the previously reported procedures shown in Scheme 1 (Section 3) [60–62].
Its characterization data, including copies of FTIR, 1H, and 13C NMR spectra, are available in Table S1
and in Figure S2. FTIR and NMR spectra of commercially available ETO are available in Figure S3.
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Scheme 1. Synthetic procedure for achieving dendri er 4. D = Dendron; A = acetonide protected;
COOH = free carboxylic group; 5 = mean generations number; DCC = N,N′-Dicyclohexylcarbodiimide;
DPTS = 4-(Dimethylamino)pyridinium 4-toluenesulfonate; DCM = dichloromethane; DOWEX H+ =
acid resins.
Concerning reagents, no further purification was performed before use, whereas solvents were
dried and purified by distillation according to standard procedures. Petroleum ether fraction with
a boiling point of 40–60 ◦C was used in this study. Acetonitrile for UV analysis was of HPLC grade.
Triple distilled water (TDW) was used for a saline phosphate buffer (PBS) and for acetonitrile/water
medium preparation. PBS and TDW were filtered through 0.22 µm filters (Millipore Sigma Life Science
Center, Burlington, MA, USA). Melting points were recorded on a Mettler Toledo MP50 melting points
and are uncorrected. FTIR spectra were acquired as films or KBr pellets on a PerkinElmer System
2000 spectrophotometer (PerkinElmer, Inc., Waltham, MA, USA) interfaced to a personal computer
(PC), operating under Turbo chrome workstation (version 6.1.1., PerkinElmer, Inc., Waltham, MA,
USA). 1H and 13C NMR spectra were performed on a Bruker Avance DPX 300 spectrometer (Bruker
Italia S.r.l., Milan, Italy) at 300 and 75.5 MHz, respectively, and assigned through DEPT-135 and
decoupling experiments.
Fully decoupled 13C NMR spectra were reported. Chemical shifts were reported in δ (parts per
million) units relative to the internal standard tetramethylsilane (δ = 0.00 ppm), and the splitting
patterns were described as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br
(broad signal). Centrifugations were performed on an ALC 4236-V1D centrifuge at 3400–3500 rpm.
Freeze-drying was performed on an EDWARDS Super Modulyo freeze dryer, ice capacity 8 kg, 8 kg/24
h, refrigeration down to −55 ◦C with 24-place Drum Manifold. Dynamic light scattering (DLS) and
Z-potential determinations were performed on a Zetasizer 3000HS (Malvern Instruments, Malvern,
UK) UV-Vis determinations were developed by a double-beam UV-Vis spectrophotometer (Perkin
Elmer, Yokohama, Japan), model LAMBDA EZ210 with an automatic wavelength accuracy of 0.1 nm,
interconnected to a PC gifted with PESSW software (Version 1.2 and Revision E, Batia InfoTech -
Informer Technologies Inc., Los Angeles, CA, USA). Quartz cells of 10 mm path length were employed
for containing sample solutions. Scanning electron microscopy (SEM) images were obtained with
a Leo Stereoscan 440 instrument (LEO Electron Microscopy Inc., Thornwood, New York, USA).
A thin layer chromatography (TLC) system employed aluminium-backed silica gel plates (Merck
DC-Alufolien Kieselgel 60 F254, Merck, Washington, DC, USA), and detection of spots was made by
UV light. Elemental analyses were determined by an EA1110 elemental analyzer (Fison Instruments,
Okehampton, Devon, UK). Organic solutions were dried over anhydrous magnesium sulphate and
were evaporated using a rotatory evaporator operating at a reduced pressure of about 10–20 mmHg.
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2.2. Entrapment Reaction of ETO in Dendrimer 4
In a test tube flamed under nitrogen gas, ETO (25.0 mg; 0.0425 mmol) was suspended in 1.3 mL
of methanol (MeOH) obtaining an ETO suspension with a concentration of 19.2 mg/mL. The solvent
was removed at reduced pressure, and the solid residue was dried in vacuum. Separately, a solution
of 4 (37.4 mg, 0.0051 mmol) in MeOH (13.0 mL) was prepared with a concentration of 2.9 mg/mL
and was added to solid ETO; a total immediate unexpected dissolution was noticed. The solution
was stirred in the dark for three days. No precipitate was formed during stirring so filtration was
not necessary, and the clear solution was simply evaporated at reduced pressure, obtaining a glassy
residue, which was subjected to three cycles of dissolution in acetone and evaporation to remove
residual MeOH. The CPX 5 was obtained as a white glassy solid (65.7 mg).
FTIR (KBr, cm−1): 3433 (OH of 4 and ETO), 2933, 1735 (C=OO of 4 and ETO), 1540 (ETO),
1506 (ETO), 1485, 1466, 1384 (ETO), 1330 (ETO), 1232 (ETO), 1116 (ETO), 1078 (ETO), 961 (ETO, 932
(ETO), 889, 863, 842 (ETO), 802, 766 (ETO), 701 (ETO), 681 (ETO), 617 (ETO), 598 (ETO). 1H NMR (300
MHz, DMSO-d6), δ (ppm): 1.01, 1.16, 1.18, 1.23, 1.34 (five s signals, 186H, CH3 of generations), 1.70 (m,
2H, CH2 propandiol), 3.52 (dd, 128H, CH2OH and 2H, CH2O propandiol, overlapped signal), 3.61
(signal of ETO), 3.95–4.20 (m, 120H, CH2O of four generations and 2H, CH2O propandiol, overlapped
signal), 4.30 (br s, 64H, OH), 4.94, 5.21, 6.03, 6.18, 6.52, 7.00 and 8.22 (signals of ETO).
2.3. Principal Components Analysis (PCA) on FTIR Spectral Data
FTIR analysis of ETO, dendrimer 4, and CPX 5 were performed by formulating them in KBr pellets.
The FTIR spectra were acquired in triplicates for each compound, and the matrix of spectral data of all
the spectra acquired were subjected to principal component analysis (PCA) using R statistical software,
free downloadable (http://cran.mirror.garr.it/mirrors/CRAN/---Garr Mirror, Milan, Italy).
2.4. Quantitative Investigations by UV Spectrophotometric Analysis: ETO Loading (DL%) Determination
The ETO loading determination by spectrophotometric UV analysis was performed according to a
method previously described [63], with slight modifications. The medium for developing the analysis
was acetonitrile (ACN):TDW 50:50 v/v. The adopted method had previously been validated by the
creators, in terms of concentrations range for linearity, accuracy, selectivity, precision, and repeatability.
2.4.1. Preparation of Calibration Curve
ETO (5 mg) was dissolved in 50 mL ACN, achieving a stock solution of 100 µg/mL. Then,
solutions at different concentrations were prepared by transferring aliquots of stock solution into a
series of 10 mL volumetric flasks, and volumes were made up with the selected medium. Five different
concentrations were prepared, i.e., 5, 10, 20, 30, and 40 µg/mL. ETO estimation was made at 286 nm,
and the measurements were obtained against a mixture of ACN/TDW as a blank. Six separate series of
solutions of ETO (5–40 µg/mL) were prepared from the stock solution and analyzed, achieving the
average absorbance (Aaverage) for each ETO concentration ± standard deviation (SD). These data were
used to build the standard ETO calibration curve.
The linear regression equation obtained was (1), the regression coefficient (R) was 0.999922, and R2
was 0.9998
y = 0.0082x − 0.0041 (1)
where y is the absorbance (A) measured at λmax = 286 nm and x is the ETO concentration (CETO) (µg/mL).
The ETO molar extinction coefficient (ε ETO) was computed according to the Lambert–Beer law (2)
A = ε b M (2)
where b is the optical path length (1 cm) and M is the ETO molar concentration and therefore it can be
simplified as A = εM.
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2.4.2. Estimation of ETO Amount (DL%) Loaded in CPX 5
By the amount of ETO employed in the complexation reaction and by the amount of CPX 5
achieved, an ETO content of around 38% w/w was initially estimated. In this regard, in order to test
samples with an ETO content value within the linearity range of the calibration curve, 25 mg of CPX 5
were dissolved in ACN (10 mL). An aliquot of 1 mL was diluted to 50 mL with the selected medium
(ACN:TDW 50:50 v/v), obtaining a concentration of 0.050 mg/mL, i.e., 50 µg/mL of CPX, which would
mean an amount of ETO around 19 µg/mL. Six aliquots of the so prepared solution were analyzed
by UV spectrometer, acquiring the relative absorbance (A) at 286 nm, and the measurements were
obtained against a mixture of ACN/TDW as a blank. The molar extinction coefficient of ETO within
the complex (εETOC) was computed according to the simplified version of the Lambert–Beer law (2).
2.5. Morphology, Size and Z-potential of CPX 5
The morphology and size of CPX 5 particles were firstly investigated by scanning electron
microscopy (SEM). In addition, the hydrodynamic size (diameter, nm) and Z-potential (mV) of 5
particles were also determined by dynamic light scattering (DLS) analysis for further confirmation of
the SEM results.
2.5.1. Scanning Electron Microscopy (SEM)
The sample was fixed on aluminum pin stubs and sputter-coated with a gold layer (30 mA for 1
min) and was examined at an accelerating voltage of 20 kV. The micrographs were recorded digitally
using the DISS 5 digital image acquisition system (Point Electronic GmbH, Halle, Germany), and the
average size of particles was provided by the instrument.
2.5.2. Dynamic Light Scattering (DLS)
The hydrodynamic size (diameter) of CPX 5, as well as polydispersion indexes (PdI),
were determined in batch mode in a low volume quartz cuvette (pathlength, 10 mm) by a photon
correlation spectroscopy (PCS) assembly equipped with a 50 mW He-Ne laser (532 nm) and
thermos-regulated at the physiological temperature of 37 ◦C. The scattering angle was fixed at 90◦.
Results were the combination of three 10-min runs for a total accumulation correlation function (ACF)
time of 30 min. Measurements were performed in PBS as a medium at the maximum concentration of
CPX 5 of 3 mg/mL. The hydrodynamic particle size result was volume-weighted and reported as the
mean of three measurements ± SD. The PdI value was reported as the mean of 10 measurements ± SD
made by the instrument on the sample. The Z-potential was measured at 37 ◦C in PBS as a medium,
and an applied voltage of 100 V was used. The CPX sample was loaded into pre-rinsed folded capillary
cells, and twelve measurements were performed.
2.6. Evaluation of CPX Solubility
The CPX solubility was determined in DMSO, ethanol (EtOH), and water, reproducing a method
previously described for similar polyester-based dendrimer drug formulations and accepted as valid [1].
Briefly, an exactly weighed amount of CPX 5 (9.3 mg) was added with a start aliquot of 250 µL of the
selected solvent. Successive aliquots of 250 µL were added (if necessary) up to a maximum of 2 mL
(water). The CPX was considered soluble when clear or milky solutions, stable in time, were obtained.
2.7. Cell Culture Conditions and Treatments
The MYCN-amplified human stage-IV NB cell line, HTLA-230, was kindly provided by
Dr. L. Raffaghello (G. Gaslini Institute, Genoa, Italy). NB cells were treated for 48 and 72 h with
1.25 µM ETO (Calbiochem, Merck KGaA, Darmstadt, Germany) or with the corresponding amount
of CPX 5 and dendrimer 4. The stock solutions of the three compounds were prepared in DMSO,
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and pilot experiments demonstrated that the final DMSO concentrations did not change any of the cell
responses analyzed.
2.8. Cell Viability Assay
Cell viability was determined by using the CellTiter 96® AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA). Briefly, cells (15,000 cells/well) were seeded into 96-well plates
(Corning Incorporated, Corning, NY, USA) and then treated. Next, the cells were incubated with
20 µL of CellTiter and the absorbance at 570/630 nm was recorded using a microplate reader (EL-808,
BIO-TEK Instruments Inc., Winooski, VT, USA).
2.9. Detection of Hydrogen Peroxide (H2O2) Production
The production of H2O2 was evaluated using 2′-7′-dichlorofluorescein-diacetate (DCFH-DA;
Merk Life Science S. r. l. Milan, Italy) according to Negre-Salvayre, et al. (2002) [64]. Briefly, cells seeded
(15,000 cells/well) and treated into 96-well plates (Corning Incorporated) were incubated with 5 µM
DCFH-DA for 30 min at 37 ◦C in the dark. At the end, the cells were washed with PBS and incubated
with 90% dimethyl sulfoxide for 10 min in the dark with shaking. Fluorescence at 485 nm ex/520 nm
em was measured by a fluorimetric plate reader (FLUOstar Optima; BMG Labtech GmbH, Offenburg,
Germany). Values were normalized to the protein content and expressed as a percentage of the
fluorescence relative to the untreated control.
2.10. Statistical Analyses
Data are expressed as means ± SD. Statistical significance of differences was determined by
one-way analysis of variances (ANOVA); p < 0.05 was considered statistically significant.
3. Results and Discussion
3.1. Entrapment of ETO in Dendrimer 4
The reduced bioavailability, the induction of several toxic effects, and the reduced selectivity
towards cancer cells limit the efficacy of chemotherapeutic drugs. For this reason, there is a strong
incentive for the development and improvement of nanoparticles containing drugs. Regarding ETO,
appealing inorganic nanohybrid constructs [50] have been successfully developed but, according to
the parameters typically associated with a good drug delivery system, a number of improvements
have been considered feasible. The Z-potential of +20.5 mV suggests a certain instability in solution,
with a tendency towards aggregations and some residual toxicity due to the positive value that could
be canceled with higher and negative Z-potentials [51–53]. In addition, an improved DL could be
achieved by exploiting dendrimers, which are nano-carriers known to be endowed with a greater
loading capacity. Dendrimers are highly branched and symmetric nanosized macromolecules and are
characterized by a monodisperse structure miming the tree’s ramification, with both internal cavities
for guest molecule entrapment and many peripheral functional groups, which offer the possibility of a
further functionalization by covalent bond [1]. They differ from traditional polymers because they
have an uncommon low intrinsic viscosity that allows their easy transport in the blood [2,3], and they
are characterized by a very low PdI of <1.1 or are even monodispersed [4]. When used as delivery
devices for drugs, they can control their molecular weight, hydrophilicity, solubility, bioavailability,
and pharmacokinetic behavior [4–6]. Thanks to their ability to establish strong interactions with
several drugs, dendrimers are endowed with easily realizable high drug loading, thus limiting drug
systemic toxicity by minimizing the initial massive drug release when parenterally administered [4–6].
Consequently, dendrimers, mainly biodegradable polyester-based ones, are considered to be excellent
carriers for drug delivery. In this regard, a fifth generation polyester-based dendrimer (namely 4),
with a high molecular weight, was selected as a carrier to entrap ETO and achieve an ETO reservoir
with improved physicochemical and therapeutic properties. The choice was justified by virtue of the
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dendrimers’ unique properties. As reported [65], the internal architecture of a dendrimer is usually
hydrophobic, thanks to hydrophobic interactions and hydrogen bond formations, and so it would
be suitable for ETO, which is a hydrophobic compound. High generation dendrimers, such as 4,
are endowed with more space to host hydrophobic drugs and are more promising for a high drug
loading [66], and the big constructs with large surfaces and high molecular weight obtainable with
such carriers are typically retained in the circulation for longer periods [67].
They behave as ‘excipients’ or permeability enhancers, they alter the barrier function of the
intestinal epithelium, and enhance the permeability of the co-administered drug [67]. Non-covalent
drug complexation, rather than covalent surface linkage, is the preferred technique for enhancing
the solubility and bioavailability of several drugs [66] to provide them with a protective shell that is
able to limit inactivating processes. The uncharged polyester-based hydrolysable architecture of 4,
known to be biodegradable [4,55,56], allows for the reduction of the risk of inducing cell death by
irreversible cell membrane damage, which is commonly associated with the use of PAMAM and b-PEI
structured matrices.
3.1.1. Chemistry
Dendrimer 4, selected as host carrier to complex ETO, was prepared as previously described,
according to Scheme 1 [60–62].
Then, dendrimer 4 dissolved in MeOH was vigorously stirred for 72 h at room temperature
in the dark with ETO (Scheme 2), achieving the complex CPX 5, which has the intuitive structure
shown in Scheme 2. The tridimensional structure of the host dendrimer (4) was obtained with the
three-dimensional Chem Draw software (PerkinElmer ChemDraw®, Milan, Italy).
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Scheme 2. Synthetic procedure for entrapping ETO in dendrimer 4.
Considering that ETO is completely not soluble in MeOH, the remarkable solubilizing action of
dendrimer 4 was evident from the initial phase of the reaction. By the addition of a methanol solution
of 4 to solid ETO, it immediately dissolved, improving its original reported max solubility (1 mg/mL)
two fold. No precipitate was formed during the three days under stirring in the dark, and finally CPX
5 was recovered by the reaction solution through the simple removal of MeOH at reduced pressure
and acetone washings. The CPX 5 was obtained in the form of a white glassy solid (65.7 mg) and
was stored on P2O5 in a dryer at r.t. Since ETO was totally complexed and entrapped in dendrimer
4, from its initial weight of 25.0 mg and that of CPX 5 (65.7 mg), a drug loading (DL%) of 38% was
preliminarily estimated.
CPX 5 was firstly qualitatively characterized by FTIR spectroscopy, whose data were also processed
by principal component analysis (PCA), and NMR analysis. UV-Vis spectrophotometric analysis was
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selected for the quantitative determination of the ETO amount entrapped in the CPX 5 and to compute
the drug loading (DL%) and the entrapment efficiency (EE%). Finally, CPX particle morphology, size,
polydispersion index (DpI), and Z-potential were determined by SEM and DLS analysis.
3.1.2. FTIR Characterization
The FTIR analysis of CPX 5 was performed by preparing KBr pellets containing 5 and acquiring
the FTIR spectra in triplicate. The absorption peaks of CPX 5 appeared as shown in Figure 4c. Another
copy of the FTIR spectra of 5 is available in the SM (Figure S4a). For comparison purposes, FTIR spectra
of 4 (Figure 4a) and ETO (Figure 4b) were also acquired in the same condition, and other copies of the
obtained spectra are available in the SM (Figure S2a and Figure S3a). FTIR analysis was significantly
diagnostic to confirm the successful complexation of ETO with 4. As shown in Figure 4 and in Figure S5,
in the FTIR spectrum of CPX 5, many bands belonging to ETO and absent in the spectrum of 4 are well
evident, thus confirming the presence of ETO complexed to the hosting dendrimer 4. The peak lists
obtained from the spectra in Figure 4 and in Figure S5 have been reported below, with the significant
peaks indicating the success of the entrapment reaction underlined.
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ETO. FTIR (KBr, cm−1): 1764, 1610, 1538, 1507, 1485, 1470, 1460, 1446, 1427, 1389, 1377, 1367, 1333,
1307, 1291, 1231, 1215, 1188, 1174, 1161, 1142, 1125, 1116, 1084, 1079, 1036, 994, 965, 949, 932, 913, 896,
874, 858, 839, 768, 753, 728, 700, 685, 664, 619, 598, 570, 519.
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Dendrimer 4. FTIR (KBr, cm−1): 1737, 1631, 1536, 1472, 1376, 1236, 1128, 1045, 912, 827, 801,
763, 657.
CPX 5. FTIR (KBr, cm−1): 1735, 1540, 1506, 1485, 1466, 1384, 1330, 1232, 1116, 1078, 961, 932, 889,
863, 842, 802, 766, 701, 681, 617, 598.
3.1.3. NMR Characterization
A further confirmation of the successful entrapment of ETO in 4 was provided by 1H NMR
spectroscopy. While the peaks belonging to ETO proton atoms are present in the spectrum region
from 1.24 to 8.22 ppm (Figure S6a), dendrimer 4 signals are not existing after 4.5 ppm (Figure S6b).
Looking at the spectrum of complex 5 (Figure 5 and Figure S6c), in the region 1–4.5 ppm, the rather
wide and intense peaks of the dendrimer polymer 4 are detectable and completely cover the possible
ETO signals. Only one peak around 3 ppm, and not sufficient to attest ETO presence, is detectable.
Differently, in the spectrum region above 4.5 ppm, even if of very low intensity, seven small signals
perfectly coinciding with ETO signals and absent in the spectrum of 4 are clearly visible.
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Figure 5. 1H NMR of CPX 5 (DMSO-d6, 300 MHz).
Usually, 1H NMR analysis is also useful for obtaining quantitative evaluations and determining
DL%. In this case, in order to quantify the ETO content in CPX 5, integrals related to very
different numbers of proton atoms should have been compared, committing substantial errors.
UV spectrophotometric determination was used in place of NMR to assess the ETO content in CPX 5.
3.1.4. Principal Components Analysis (PCA) on FTIR Spectral Data
In order to get a more reliable information concerning CPX 5 chemical composition from FTIR
spectral data, it was of great help to resort to a specific analytical technique that was able to work on
very complex data sets, known as principal component analysis (PCA). This technique can reduce
multi-dimensional data to a small number of new variables—principal components (PCs) [68]. A more
detailed description of the PCA chemometric tool is available in the Supplementary Materials Section
S5. In this work, the data of the nine spectra obtained by the FTIR analysis made in triplicate on
the three compounds under study (4, 5, and ETO), were arranged into a matrix of variables that
was subjected to PCA. Ninety-nine percent of the explained variance was provided by PC1 and PC2,
and the results are reported as bi-plot and score plot in Figure S7. The desired information was clearly
observable on PC2. In this regard, both in bi-plot and score plot, by observing the relative positions of
4, 5, and ETO on PC2, it appears that 5 is located in the middle between 4 and ETO and slightly closer
to 4 rather than to ETO. Such disposition suggests that the chemical composition of 5 is a mixture of
ETO and 4 in a ratio slightly inferior to 50% and confirms the presence of ETO inside the complex.
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3.1.5. Quantitative Investigations by UV Spectrophotometric Analysis: ETO Loading
(DL%) Determination
For a correct drug content estimation, sensitive, simple, and cost effective methods are needed,
including UV, visible, fluorescence, and high performance liquid chromatography. For the estimation
of ETO, the most reported methods are based on liquid chromatographic technique utilizing UV [69,70],
fluorescence [71], and electrochemical [72] detectors or the HPLC method utilizing gradient technique
(USP, 2003). These reported methods are tedious, expensive, complicated, and involve lengthy
extraction procedures [73–75]. Simple UV and spectrofluorimetric methods have been found to be
very suitable for the estimation of drug content, entrapment efficiency, and in vitro release studies.
Therefore, a previously reported UV method [63], slightly modified, has been adopted in this work to
estimate ETO content in CPX 5.
Calibration Curve
Similarly to the value reported for the UV spectrum of ETO acquired in ACN [63], i.e., λ = 285 nm,
the UV spectra of ETO acquired in this study in ACN/TDW 50:50 showed a well-defined maximum
at λ = 286 nm (Figure S8a), and this wavelength was chosen as the analytical wavelength to build
up the standard ETO calibration curve and then to quantify the amount of ETO in CPX 5. The UV
spectra of ETO in the selected medium at the different concentrations are shown in Figure S8a. Six
separate series of standard solutions of ETO at concentrations in the range 5–40 µg/mL (identified as
the linearity range) were prepared and analyzed by reading absorbance at λ = 286 nm. The average
absorbance (Aaverage) values ± SD measured for each concentration of ETO (CETO) (n = 6) have been
reported in Table S2.
Aaverage and CETO (µg/mL) data in Table S2 were used to build up the standard ETO calibration
curve shown in Figure S8b whose Equation (1) has been reported in the Material and Methods
(Section 2.4.1) and whose very high coefficient of correlation (R) assured a condition of linearity.
The standard error of prediction was 0.2064, and the predicted ETO concentrations (CETOp) were
calculated for each sample and reported in Table S2 together with the residuals. The real concentrations
versus the predicted ones are reported in a graph (Figure S8c), and the linear regression equation
correlating the two data sets is observable in Figure S8c. The coefficient of correlation R was 0.99993,
and R2 was 0.99998.
Aaverage measured and ETO µM concentrations (last column in Table S2) were used to calculate
the molar extinction coefficient of ETO (εETO), according to the simplified version of the Lambert–Beer
law (2), usable when the optical length path is 1 cm.
Briefly, Aaverage values versus CETO concentrations (µM) were plotted on a graph (Figure S8d),
and it was verified that the intercept was not significantly different from zero. Consequently, the linear
regression equation with intercept zero obtained was (3), the regression coefficient (R) was 0.99992,
and R2 was 0.9994.
y = 0.0047x (3)
where y is the absorbance (A) measured at λ = 286 nm and x is the CETO (µM).
In a graph of A versus C, the slope is the molar extinction coefficient (ε) of the compound under
study. In this regard, the molar extinction coefficient of ETO (εETO) was 0.0047 µM−1 L cm−1, i.e., 4700
M−1 L cm−1.
Estimation of ETO Amount in CPX 5 (DL%) and of Entrapment Efficiency (EE%)
Six aliquots of a solution of CPX 5, prepared at a concentration of 50 µg/mL, were analyzed by
UV spectrometer, acquiring the absorbance at λ = 286 nm. By using Equation (1), the correspondent
concentrations of ETO were determined, and by using the simplified form of the Lambert–Beer law 2
the correspondent molar extinction coefficients of ETO within the complex (εETOC) were computed.
Antioxidants 2020, 9, 50 13 of 23
The measured absorbance (A), the relative ETO concentrations (CETO), and the molar extinction
coefficients of ETO within the complex (εETOC) for each aliquot have been reported in Table 1.
Table 1. Values of A, CETO, and εETOC obtained for the six aliquots of a 50 µg/mL sample of CPX 5.







The average absorbance (Aaverage) resulted to be 0.149± 0.0021, and the average ETO concentration
(CETO average) in the sample of CPX 5 analyzed, resulted to be 18.7 ± 0.24 µg/mL. The drug loading
(DL%) was calculate by:
DL% =
Weight of etoposide in CPX
Weight of CPX
× 100
It resulted to be 37.4% w/w and was therefore both very satisfying and remarkably improved in
respect of ETO nanocomposites prepared by Qin et al. [50].
The molar extinction coefficient of ETO within the complex (εETOC) at the obtained concentration of
18.7 µg/mL, calculated by the Lambe–Beer law, was 4690 M−1 L cm−1. The molar extinction coefficient
of free ETO (εETO) provided by Equation (3) was 4700 M−1 L cm−1, thus demonstrating that there has
been no significant variation in the drug extinction coefficient with its complexation and thus validating
the UV proposed method. For further confirmation, ETO concentration (µg/mL) was also calculated
by using the molar extinction coefficient of the not complexed ETO (0.0047 µM−1 L cm−1) and the
simplified form of the Lambert–Beer law 2. The result was CETO = 31.7 µM, i.e., 0.0317 µmol/mL and
18.66 µg/mL, which is within the limit values of the ETO concentration obtained through the calibration
curve (18.46–18.94).
Once the content of ETO for a given weight of CPX 5 was known, the ETO moles (molesETO)
loaded per dendrimer 4 mole (mole4) were calculated, and from this data the molecular weight (MW)
of 5 was computed (Table 2). In particular, MW was calculated according to a procedure previously
reported in the literature and accepted as valid [1,5,6] without resorting to widely used but very
expansive methods such as Matrix-Assisted Laser Desorption/Ionization-Time Of Flight (MALDI-TOF)
mass spectrometry (MS). In addition, the ETO entrapment efficiency (EE%), which is defined by the
concentration of the incorporated material detected in the formulation over the initial concentration
used to make the formulation, was also calculate by:
EE% =
Weight of etoposide in CPX
Weight of ETO fed initially
× 100
Table 2. Estimated ETO amount in a 50 µg/mL sample of CPX 5 expressed in µg, as DL% w/w, as EE%
w/w, and as ETO moles (molesETO) loaded per dendrimer 4 mole (mole4), and computed molecular













31.3, 0.0043 18.7, 0.032 37.4 89.3 7.4 11,631
The result was found to be 89.3% and has been reported in Table 2. Concerning ETO-loaded
nanoparticles prepared in the last decade, only very high dimensioned pegylated liposomal ETO
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nanoparticles of 491 nm, characterized by a limited DL% of 10%, proved to have a very high entrapment
efficiency of 99% [76]. In other cases, the ETO EE% was either very low (4–14%) [77] or, though high
(75–84%) [78], were not as high as the EE% achieved in this study by using dendrimer 4. Only recently,
Thiyagarajan et al. [79], have prepared a series of polymeric nanoparticles containing ETO for targeting
cancer cells that had a high DL% (62–90%) and in some cases very high EE% (49–94%).
3.1.6. Morphology, Size, and Z-potential of CPX 5
The SEM image of CPX 5 particles is shown in Figure 6, while the average particle size, provided
by the instrument, is reported in Table 3.
Antioxidants 2019, 8, x FOR PEER REVIEW 14 of 22 
 
Figure 6. SEM image of CPX 5 particles. 
Table 3. CPX 5 particle hydrodynamic size, PdI, and Z-potential at 37 °C by dynamic light scattering 
(DLS) analysis and average particles size by SEM analysis. 
Z-AVE Size (nm) 1 PdI 2 Average Particles Size (nm) by SEM Analysis Z-potential (mV) 3 
69.2 ± 1.08 0.536 ± 0.002 76.25 ± 17.3 −45 ± 0.34 
1 Z-AVE size determinations = 3. 2 PdI determination = 10. 3 Z-potential determinations = 12. 
For a good functioning of a nano delivery system, the size and morphology of nanoparticles play 
a key role. These features have a great influence on a drug delivery system’s distribution, toxicity, 
targeting ability, and drug release profile [80]. For biomedical applications, the preferential size has 
to be less than 200 nm, with an optimal of 100–200 nm for assuring an efficient cellular up-take [81]. 
In this regard, in a reported study [82], drug delivery systems with 100 nm nanoparticles exhibited a 
2.5-fold greater uptake compared to 1 µm diameter particles and a 6-fold greater uptake than 10 µm 
particles. Particles of 200 nm or larger tend to activate the lymphatic system and are removed from 
circulation quicker [81]. Particle size of about 100 nm encompass larger surface area to volume ratio 
and allow a more effective and fast drug release because more of the drug is closer to the surface of 
the particle [83]. In addition, particles at a dimension of 100 nm could also pass through the blood-
brain barrier (BBB) and deliver sufficient amounts of drug, avoiding immediate clearance by the 
lymphatic system [80]. 
CPX 5 particles in SEM images show a spherical morphology, which suggests a very large 
surface area that typically increases the drug delivery system’s (DDS’s) systemic retention time and 
positively affects their bio-efficiency [67,80]. The mean particle size of 5 was 76 nm, i.e., slightly 
inferior to 100 nm, which is reported as the ideal size value for nanoparticle drug formulations 
suitable for biomedical applications [80]. 
Concerning nanomaterial sized at values <100 nm, McMillian et al. [84] reported that, thanks to 
their physical properties, they possess a unique biologic potential for biomedical applications. Such 
particles, and therefore the ones of CPX 5, represent attractive systems for the treatment of cancer 
and heart and lung, blood, and inflammatory disorders, and infectious diseases, including central 
nervous system disorders. 
For further confirmation of the SEM results, the particle hydrodynamic size (diameter, nm) of 
CPX 5 was measured using DLS analysis, and the result matched the SEM ones with a very small 
error of 7 nm. It was reported as the intensity-weighted average (Z-AVE) [N (degree of freedom) = 3] 
in Table 4, and size distribution has been shown in Figure S9. The PdI value (n = 10) was 0.5 and was 
therefore in the range of PdI recently reported for promising ETO nanoparticles formulations [79]. In 
addition, by DLS technique, the Z-potential (mV) of CPX 5 particles was also measured, for the 
purpose of having an idea of physical stability of 5 in aqueous solution, for investigating the possible 
tendency of the particles to form aggregates, and for finding its possible toxicity. The result has been 
reported in Table 3. 
Figure 6. SEM image of CPX 5 particles.
Table 3. CPX 5 particle hydrodynamic size, PdI, and Z-potential at 37 ◦C by dynamic light scattering
(DLS) analysis and average particles size by SEM analysis.
Z-AVE Size (nm) 1 PdI 2
Average Particles Size (nm) by SEM
Analysis Z-potential (mV)
3
69.2 ± 1.08 0.536 ± 0.002 76.25 ± 17.3 −45 ± 0.34
1 Z-AVE size determinations = 3. 2 PdI determination = 10. 3 Z-potential determinations = 12.
For a good functioning of a nano delivery system, the size and morphology of nanoparticles play
a key role. These features have a great influence on a drug delivery system’s distribution, toxicity,
targeting ability, and drug release profile [80]. For biomedical applications, the preferential size has to
be less than 200 nm, with an optimal of 100–200 nm for assuring an efficient cellular up-take [81]. In this
regard, in a reported study [82], drug delivery systems with 100 nm nanoparticles exhibited a 2.5-fold
greater uptake compared to 1 µm diameter particles and a 6-fold greater uptake than 10 µm particles.
Particles of 200 nm or larger tend to activate the lymphatic system and are removed from circulation
quicker [81]. Particle size of about 100 nm encompass larger surface area to volume ratio and allow a
more effective and fast drug release because more of the drug is closer to the surface of the particle [83].
In addition, particles at a dimension of 100 nm could also pass through the blood-brain barrier (BBB)
and deliver sufficient amounts of drug, avoiding immediate clearance by the lymphatic system [80].
CPX 5 particles in SEM images show a spherical morphology, which suggests a very large surface
area that typically increases the drug delivery system’s (DDS’s) systemic retention time and positively
affects their bio-efficiency [67,80]. The mean particle size of 5 was 76 nm, i.e., slightly inferior to
100 nm, which is reported as the ideal size value for nanoparticle drug formulations suitable for
biomedical applications [80].
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Concerning nanomaterial sized at values <100 nm, McMillian et al. [84] reported that, thanks to their
physical properties, they possess a unique biologic potential for biomedical applications. Such particles,
and therefore the ones of CPX 5, represent attractive systems for the treatment of cancer and heart
and lung, blood, and inflammatory disorders, and infectious diseases, including central nervous
system disorders.
For further confirmation of the SEM results, the particle hydrodynamic size (diameter, nm) of
CPX 5 was measured using DLS analysis, and the result matched the SEM ones with a very small error
of 7 nm. It was reported as the intensity-weighted average (Z-AVE) [N (degree of freedom) = 3] in
Table 4, and size distribution has been shown in Figure S9. The PdI value (n = 10) was 0.5 and was
therefore in the range of PdI recently reported for promising ETO nanoparticles formulations [79].
In addition, by DLS technique, the Z-potential (mV) of CPX 5 particles was also measured, for the
purpose of having an idea of physical stability of 5 in aqueous solution, for investigating the possible
tendency of the particles to form aggregates, and for finding its possible toxicity. The result has been
reported in Table 3.
Table 4. Comparison between solubility of free ETO and ETO-loaded CPX 5.
Solvent ETO CPX 5 Improvement (times)
DMSO max 58.9 mg/mL [85] 78.8 mg/mL 1.3
EtOH 0.78 mg/mL [86] >37.2 mg/mL >47.7
H2O 0.012–0.029 mg/mL [86,87] 4.7 mg/mL 162.1–391.7
Z-potential is the potential difference between the dispersion medium and the stationary layer of
fluid attached to particles. It is a measure of the electrical charge of particles that are suspended in liquid
and is also crucial for nanoparticles-cell interactions. Low Z-potential favors the particles binding
to low serum proteins and a longer circulation in blood. Values <5 mV may lead to agglomeration
of particles conferring physical instability in solution. On the contrary, Z-potential >30 mV, either
positive or negative, leads to monodispersity and good physical stability in solution [45,46] Finally,
high positive Z-potential values are correlated to high cytotoxicity while negative values allow high cell
viability [47]. In this regards, the CPX 5 nanoparticles that proved to possess a Z-potential of −45 mV
± SD can be rationally considered stable in water solution, with no tendency to form aggregates and
are endowed with low cytotoxicity.
3.1.7. Evaluation of CPX 5 Solubility
According to a reported method used to evaluate the solubility of two ellagic acid-loaded
polyester-based dendrimers [1], the CPX 5 solubility was determined in DMSO and in the
commonly biocompatible hydrophilic solvents used for biomedical applications, i.e., EtOH and
water. DMSO dissolves very well both free ETO and CPX 5, but it is known to be hazardous for humans
and not advisable for clinical applications. CPX 5 solubility in DMSO was, however, assessed to have
an ideal maximal concentration achievable in biological studies on cell models, usually performed
in DMSO, as in this study. Concerning biocompatible solvents, free ETO is poorly soluble in EtOH
and practically non-soluble in water. By its entrapment inside the dendrimer architecture of 4, ETO
solubility was improved in all the solvents considered. CPX 5 resulted to be more soluble than ETO by
48 times in EtOH and by 162–392 times in water (Table 4).
CPX 5 gave clear and stable solutions in DMSO and EtOH, while a fine suspension with pH =
7.4, stable along time, was achieved in water. Water fine suspension, obtained at a concentration of
4.7 mg/mL, became clear with the addition of 150 µL of EtOH. Biocompatible ethanol, water/ethanol
solutions, and water suspensions of CPX 5 can be considered suitable for oral administration of ETO.
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3.2. Biological Activity of CPX 5 on Human NB Cells
3.2.1. CPX 5 Revealed a Synergistic Cytotoxic Effect Exerted by Dendrimer 4 per se and by the
Complexed ETO Slowly Released over Time
HTLA-230 NB cells were treated with 1.25 µM ETO, CPX 5 (in a dose capable of providing 1.25 µM
ETO), and dendrimer 4 (at the same dose of that contained in the administered CPX 5) for 48 and
72 h, and the effect of all treatments on NB cell viability was investigated. After 48 h of exposure to
ETO, dendrimer 4, or CPX 5, the effects were comparable, since all single treatments reduced NB cell
viability by 40–45%. Interestingly, comparing the effects induced by the 72 h treatment, CPX 5 was
able to significantly reduce cell viability by 65% in respect to untreated cells and by 30% in respect to
ETO-treated cells (Figure 7).
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These results demonstrate that the ETO entrapment in dendrimer 4, although with a delayed
effect, increases the cytotoxicity f the drug, and this effect is probably the result of two mechanisms
that act sy ergistically. On one hand, CPX 5 guarantees a slow and protracted release of ETO over
time, whereas, on the other hand, it adds a greater cytotoxic effect of the host dendrimer (4) to that
of the delivered ETO. A similar result has been observed in another study employing ETO-loaded
poly (lactide-co-glycolide) nanoparticles in which a sustained release of the drug was maintained
until 72 h [88]. In addition, it has been reported that pegylated liposomal nanoparticles, containing a
non-clinically useful ETO concentration, had a greater cytotoxic effect than that of the free drug [89].
However, in our experimental model, CPX 5 would appear to be a more efficacious delivery system
because it significantly increases the cytotoxic effect of an ETO dose comparable to that commonly
used to treat NB patients [90].
3.2.2. CPX 5 Potentiates the Cytotoxic Action of ETO by Increasing Reactive Oxygen Species
(ROS) Produc ion
As shown in Figure 8, CPX 5 treatment increased the production of ROS in a time-dependent
manner. In particular, compared to control cells, ROS levels were increased by 70% and 190% after 48
and 72 h, respectively, while the treatment with free ETO or dendrimer 4 stimulated ROS production
by 60% and 80% after 48 and 72 h (Figure 8). To our knowledge, ETO is well known to exert its
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cytotoxic action by increasing ROS production [91,92], while a pro-oxidant effect of nanoparticles
was reported only for polyamidoamine dendrimers (PAMAMs) [93]. Our present data shows that
dendrimer 4, which was able per se to increase ROS production, when included in the formation of
CPX 5 markedly enhanced the pro-oxidant action of ETO, thus creating conditions of oxidative stress
capable of triggering cell death (Figure 7).Antioxidants 2019, 8, x FOR PEER REVIEW 17 of 22 
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4. Conclusions
As in the case of many chemotherapeutic drugs, also for ETO, the efficacy is often limited by the
reduced bioavailability, the induction of several toxic effects that forces to limit dosage, the metabolism
or environmental-induced inactivation, and the reduced selectivity towards cancer cells.
An appealing strategy, currently being studied and which is giving promising results, is the
administration of chemotherapeutic drugs entrapped in nanoparticles, including the well-known
dendrimers endowed with nonpareil properties.
In this context, ETO has been successfully combined with a lab-made biodegradable dendrimer
nanoparticles (4) that, being uncharged differently from the well-known PAMAMs, are respectful
to cell membranes and do not provoke irreversible cell damage. It is important to note that the
structure and the chemical composition of the ETO-loaded dendrimer achieved (CPX 5) has been
qualitatively and quantitatively investigated by FTIR, NMR, and UV spectroscopy, and a more in
depth interpretation of FTIR spectral data by performing PCA has been obtained and provided.
In addition, by SEM and DLS analysis, CPX 5 showed a spherical morphology, a particle size of
about 70 nm, and a Z-potential of −45 mV, matching the values that typically assure low toxicity,
low poly dispersion index, high residence time in blood, and stability in solution. The drug loading
was 37%, the entrapment efficiency was 89%, and the solubility of ETO in biocompatible solvents
was amazingly improved (390 times in H2O). Experiments performed to assess CPX 5 bioactivity
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on NB cells in comparison with ETO and dendrimer 4 alone demonstrated unexpectedly that the
hosting dendrimer 4 per se is able to exert a ROS-mediated cytotoxicity comparable to that of free ETO.
Interestingly, in CPX 5, the bioactive scaffold of dendrimer 4 has been found to act in synergy with
the complexed ETO that is released in a protracted manner, determining a significant improvement
of the cytotoxic activity of free ETO. In addition, having a high drug loading and providing the
hosted ETO with a protective shell, CPX 5 can guarantee an improvement of the ROS-mediated
cytotoxic action of ETO for a long time. Consequently, although preliminary, our data suggests that
CPX 5, endowed with a considerably improved water solubility and a significant scaffold-assisted
anti-cancer activity, can become a promising formulation for the protracted release of ETO in order to
sensitize NB cells. In conclusion, collectively, these results suggest that dendrimer 4, having per se a
ROS-mediated cytotoxicity, could be considered an efficient chemiosensitizer that, inducing oxidative
stress, weakens cancer cells facilitating the trigger of drug-induced oxidative death. The already very
interesting and satisfying results obtained by combining ETO with the not functionalized dendrimer 4
could be further improved by the partially esterification of the peripheral hydroxyls of 4 with targeting
molecules such as folic acid that is recognized by cancer cells for a more selective action and reduced
toxicity for healthy cells.
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